⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 13, 2020CancerOpen Access

Particle radiation therapy in the management of malignant glioma: Early experience at the Shanghai Proton and Heavy Ion Center

Lin Kong Jinsong Wu Jing Gao Xianxin Qiu Jing Yang Jiyi Hu Weixu Hu Ying Mao Jiade J. Lu

View Full Paper

Ask AI

Bookmark

Share

Abstract

Particle radiotherapy produced 18-month OS and PFS rates of 72.8% and 59.8%, respectively, with acceptable adverse effects in patients with high-grade glioma. Particle radiotherapy at a dose ≥60 gray-equivalents appears to be safe and potentially effective.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kong et al. (2020) studied this question.

synapsesocial.com/papers/69d69152ce5e22ae23db829b https://doi.org/10.1002/cncr.32828

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Cancer risks associated with BRCA1 and BRCA2 : Overview and managementCancer · Wed,
2Real‐world outcomes in circulating tumor DNA–detected isocitrate dehydrogenase 1–mutant cholangiocarcinoma: First‐line gemcitabine and cisplatin with versus without immunotherapyCancer · Wed,
3Increased risk of stroke after a new cancer diagnosis—Where are the knowledge gaps currently?Cancer · Tue,
4Evolving role of proton therapy in contemporary oncologyCancer · Tue,
5Evaluation of early C‐reactive protein kinetics as an early response marker in biliary tract cancer treated with combined chemoimmunotherapy: A multicenter observational studyCancer · Tue,

More from Cancer

Blood‐based biomarkers in patients with recurrent, persistent, or metastatic endometrial cancer treated with olaparib and cediranib: Results from NRG‐GY012Wed,
Delays in breast cancer presentation, diagnosis, and treatment in young womenMon,
Who is eligible for lung cancer screening, and where are they? National subpopulation estimates of people eligible for lung cancer screeningFri,
Perioperative immunotherapy in head and neck squamous cell carcinomaWed,
Redefining leptomeningeal metastasis in non–small cell lung cancer: From terminal complication to molecularly managed diseaseTue,